CD274 and non-small cell lung carcinoma: Following the emergence of molecular‐targeted agents, such as tyrosine kinase inhibitors, newly developed agents of immune checkpoint inhibitors (ICIs), programmed cell death‐ligand 1 (PD‐L1), and programmed cell death‐1 (PD‐1) inhibitors have rapidly become the standard‐of‐care for NSCLC.